266 related articles for article (PubMed ID: 36562292)
1. The G protein-coupled receptor ligand apelin-13 ameliorates skeletal muscle atrophy induced by chronic kidney disease.
Enoki Y; Nagai T; Hamamura Y; Osa S; Nakamura H; Taguchi K; Watanabe H; Maruyama T; Matsumoto K
J Cachexia Sarcopenia Muscle; 2023 Feb; 14(1):553-564. PubMed ID: 36562292
[TBL] [Abstract][Full Text] [Related]
2. Indoxyl sulfate potentiates skeletal muscle atrophy by inducing the oxidative stress-mediated expression of myostatin and atrogin-1.
Enoki Y; Watanabe H; Arake R; Sugimoto R; Imafuku T; Tominaga Y; Ishima Y; Kotani S; Nakajima M; Tanaka M; Matsushita K; Fukagawa M; Otagiri M; Maruyama T
Sci Rep; 2016 Aug; 6():32084. PubMed ID: 27549031
[TBL] [Abstract][Full Text] [Related]
3. Formononetin ameliorates muscle atrophy by regulating myostatin-mediated PI3K/Akt/FoxO3a pathway and satellite cell function in chronic kidney disease.
Liu L; Hu R; You H; Li J; Liu Y; Li Q; Wu X; Huang J; Cai X; Wang M; Wei L
J Cell Mol Med; 2021 Feb; 25(3):1493-1506. PubMed ID: 33405354
[TBL] [Abstract][Full Text] [Related]
4. Potential therapeutic interventions for chronic kidney disease-associated sarcopenia via indoxyl sulfate-induced mitochondrial dysfunction.
Enoki Y; Watanabe H; Arake R; Fujimura R; Ishiodori K; Imafuku T; Nishida K; Sugimoto R; Nagao S; Miyamura S; Ishima Y; Tanaka M; Matsushita K; Komaba H; Fukagawa M; Otagiri M; Maruyama T
J Cachexia Sarcopenia Muscle; 2017 Oct; 8(5):735-747. PubMed ID: 28608457
[TBL] [Abstract][Full Text] [Related]
5. Apelin/APJ system: A critical regulator of vascular smooth muscle cell.
Luo X; Liu J; Zhou H; Chen L
J Cell Physiol; 2018 Jul; 233(7):5180-5188. PubMed ID: 29215755
[TBL] [Abstract][Full Text] [Related]
6. Apelin and Elabela/Toddler; double ligands for APJ/Apelin receptor in heart development, physiology, and pathology.
Kuba K; Sato T; Imai Y; Yamaguchi T
Peptides; 2019 Jan; 111():62-70. PubMed ID: 29684595
[TBL] [Abstract][Full Text] [Related]
7. ELABELA-APJ axis protects from pressure overload heart failure and angiotensin II-induced cardiac damage.
Sato T; Sato C; Kadowaki A; Watanabe H; Ho L; Ishida J; Yamaguchi T; Kimura A; Fukamizu A; Penninger JM; Reversade B; Ito H; Imai Y; Kuba K
Cardiovasc Res; 2017 Jun; 113(7):760-769. PubMed ID: 28371822
[TBL] [Abstract][Full Text] [Related]
8. Suppression of muscle wasting by the plant-derived compound ursolic acid in a model of chronic kidney disease.
Yu R; Chen JA; Xu J; Cao J; Wang Y; Thomas SS; Hu Z
J Cachexia Sarcopenia Muscle; 2017 Apr; 8(2):327-341. PubMed ID: 27897418
[TBL] [Abstract][Full Text] [Related]
9. Irisin Ameliorated Skeletal Muscle Atrophy by Inhibiting Fatty Acid Oxidation and Pyroptosis Induced by Palmitic Acid in Chronic Kidney Disease.
Zhou T; Wang S; Pan Y; Dong X; Wu L; Meng J; Zhang J; Pang Q; Zhang A
Kidney Blood Press Res; 2023; 48(1):628-641. PubMed ID: 37717561
[TBL] [Abstract][Full Text] [Related]
10. The apelin/APJ system in the regulation of vascular tone: friend or foe?
Rikitake Y
J Biochem; 2021 Apr; 169(4):383-386. PubMed ID: 33169143
[TBL] [Abstract][Full Text] [Related]
11. Hypoxic Exercise Training Promotes apelin/APJ Expression in Skeletal Muscles of High Fat Diet-Induced Obese Mice.
Ji W; Gong L; Wang J; He H; Zhang Y
Protein Pept Lett; 2017; 24(1):64-70. PubMed ID: 27834140
[TBL] [Abstract][Full Text] [Related]
12. Advanced oxidation protein products contribute to chronic kidney disease-induced muscle atrophy by inducing oxidative stress via CD36/NADPH oxidase pathway.
Kato H; Watanabe H; Imafuku T; Arimura N; Fujita I; Noguchi I; Tanaka S; Nakano T; Tokumaru K; Enoki Y; Maeda H; Hino S; Tanaka M; Matsushita K; Fukagawa M; Maruyama T
J Cachexia Sarcopenia Muscle; 2021 Dec; 12(6):1832-1847. PubMed ID: 34599649
[TBL] [Abstract][Full Text] [Related]
13. AST-120 ameliorates lowered exercise capacity and mitochondrial biogenesis in the skeletal muscle from mice with chronic kidney disease via reducing oxidative stress.
Nishikawa M; Ishimori N; Takada S; Saito A; Kadoguchi T; Furihata T; Fukushima A; Matsushima S; Yokota T; Kinugawa S; Tsutsui H
Nephrol Dial Transplant; 2015 Jun; 30(6):934-42. PubMed ID: 25878055
[TBL] [Abstract][Full Text] [Related]
14. Apelin/APJ system: A novel therapeutic target for locomotor system diseases.
Luo J; Liu W; Feng F; Chen L
Eur J Pharmacol; 2021 Sep; 906():174286. PubMed ID: 34174264
[TBL] [Abstract][Full Text] [Related]
15. The biological function of ELABELA and APJ signaling in the cardiovascular system and pre-eclampsia.
Liu Y; Wang L; Shi H
Hypertens Res; 2019 Jul; 42(7):928-934. PubMed ID: 30626933
[TBL] [Abstract][Full Text] [Related]
16. Targeting drugs to APJ receptor: From signaling to pathophysiological effects.
Huang Z; He L; Chen Z; Chen L
J Cell Physiol; 2018 Jan; 234(1):61-74. PubMed ID: 30070701
[TBL] [Abstract][Full Text] [Related]
17. Expression of apelin and apelin receptor (APJ) in porcine ovarian follicles and in vitro effect of apelin on steroidogenesis and proliferation through APJ activation and different signaling pathways.
Rak A; Drwal E; Rame C; Knapczyk-Stwora K; Słomczyńska M; Dupont J; Gregoraszczuk EL
Theriogenology; 2017 Jul; 96():126-135. PubMed ID: 28532828
[TBL] [Abstract][Full Text] [Related]
18. Elabela-apelin-12, 17, 36/APJ system promotes platelet aggregation and thrombosis via activating the PANX1-P2X7 signaling pathway.
Chen Z; Luo X; Liu M; Jiang J; Li Y; Huang Z; Wang L; Cao J; He L; Huang S; Hu H; Li L; Chen L
J Cell Biochem; 2023 Apr; 124(4):586-605. PubMed ID: 36855998
[TBL] [Abstract][Full Text] [Related]
19. Apelin/ELABELA-APJ system in cardiac hypertrophy: Regulatory mechanisms and therapeutic potential.
Pang B; Jiang YR; Xu JY; Shao DX; Hao LY
Eur J Pharmacol; 2023 Jun; 949():175727. PubMed ID: 37062502
[TBL] [Abstract][Full Text] [Related]
20. Apelin and APJ orchestrate complex tissue-specific control of cardiomyocyte hypertrophy and contractility in the hypertrophy-heart failure transition.
Parikh VN; Liu J; Shang C; Woods C; Chang AC; Zhao M; Charo DN; Grunwald Z; Huang Y; Seo K; Tsao PS; Bernstein D; Ruiz-Lozano P; Quertermous T; Ashley EA
Am J Physiol Heart Circ Physiol; 2018 Aug; 315(2):H348-H356. PubMed ID: 29775410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
